Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23

Lei Lei Wu

News Reporter

Bicara’s bispecific antibody treatment on top of Keytruda led to tumor shrinkage in about half of patients with head and neck cancer that has relapsed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Ear­ly da­ta show Bicara’s bis­pe­cif­ic helps shrink head and neck can­cers when com­bined with Keytru­da: #AS­CO23

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?